Image

Cardiac Rehabilitation in Decompensated Heart Failure

Cardiac Rehabilitation in Decompensated Heart Failure

Recruiting
45-65 years
All
Phase N/A

Powered by AI

Overview

Heart failure is a common clinical condition that often leads to reduced exercise tolerance, shortness of breath, and poor quality of life. Many patients with heart failure also develop weakness of the inspiratory muscles, which contributes to limited physical activity and worsening functional capacity. Inspiratory muscle training (IMT) has been suggested as a useful rehabilitation method to improve respiratory muscle strength and exercise tolerance. In addition, functional electrical stimulation (FES) of the lower limb muscles may help activate skeletal muscles and improve functional performance in patients who cannot tolerate conventional exercise.

This randomized controlled study aims to investigate the effect of combining inspiratory muscle training with functional electrical stimulation of the lower limbs in patients with decompensated heart failure. A total of 135 hospitalized patients with decompensated heart failure will be recruited from the Cardiology Department at Beni-Suef University Hospital and randomly assigned into three groups. Group A (45 patients) will receive routine medical treatment in addition to inspiratory muscle training combined with functional electrical stimulation. Group B (45 patients) will receive routine medical treatment with inspiratory muscle training only. Group C (45 patients) will receive routine medical treatment alone.

The intervention will start during hospitalization and will continue for four weeks. The study will evaluate the effects of these interventions on cardiac function, inspiratory muscle strength, and functional capacity as primary outcomes. Secondary outcomes will include dyspnea severity, quality of life, heart rate, oxygen saturation, hand grip strength, and maximum expiratory pressure. The findings of this study may help clarify the potential role of combining inspiratory muscle training with functional electrical stimulation as part of cardiac rehabilitation in patients with decompensated heart failure.

Description

Heart failure is a progressive clinical syndrome in which the heart is unable to maintain adequate cardiac output to meet the body's metabolic demands. Decompensated heart failure represents an acute or subacute deterioration requiring hospitalization and is associated with significant morbidity, prolonged hospital stays, and high readmission rates. Beyond the primary cardiac impairment, patients with decompensated heart failure commonly develop secondary systemic consequences, including respiratory muscle dysfunction and peripheral skeletal muscle abnormalities, both of which contribute independently to exercise intolerance, symptom burden, and poor functional outcomes.

Inspiratory muscle weakness has been identified in approximately 30-50% of patients with heart failure and is believed to result from a combination of diaphragmatic underperfusion, chronic hyperventilation, and systemic inflammatory and catabolic processes. This weakness leads to increased work of breathing, ventilatory inefficiency, and heightened perception of dyspnea, creating a vicious cycle that further limits physical activity and accelerates functional decline. Inspiratory muscle training (IMT) targets this mechanism by applying progressive resistive loading to the inspiratory muscles, promoting improvements in diaphragmatic strength, ventilatory efficiency, and autonomic modulation. Several studies have demonstrated favorable effects of IMT on inspiratory muscle performance, exercise capacity, and quality of life in stable heart failure populations; however, evidence regarding its application during the acute decompensated phase remains limited.

Peripheral skeletal muscle dysfunction in heart failure is characterized by a shift from type I oxidative to type II glycolytic muscle fibers, reduced mitochondrial density, impaired oxygen utilization, and muscle atrophy driven by disuse, neurohormonal activation, and systemic inflammation. These changes are particularly pronounced during periods of decompensation and prolonged bed rest. Functional electrical stimulation (FES) offers a passive approach to muscle activation that bypasses the cardiovascular demand of voluntary exercise, making it a potentially suitable intervention for hemodynamically unstable or severely deconditioned patients. FES-induced muscle contractions have been shown to improve local blood flow, enhance oxidative enzyme activity, and promote favorable fiber-type remodeling in heart failure populations.

Despite the established individual benefits of IMT and FES, no study to date has investigated the combined application of these two modalities in patients hospitalized with decompensated heart failure. The physiological rationale for combining them is based on the concept of addressing both central (respiratory muscle) and peripheral (skeletal muscle) components of exercise intolerance simultaneously, which may produce additive or synergistic improvements in functional capacity and clinical outcomes compared to either intervention alone.

This study hypothesizes that the addition of combined IMT and FES to routine medical treatment will result in greater improvements in cardiac function, inspiratory muscle strength, and functional capacity compared to IMT alone or medical treatment alone in patients with decompensated heart failure. The findings may contribute to the development of early, comprehensive cardiac rehabilitation strategies for this high-risk population.

Eligibility

Inclusion Criteria:

  • Aged from 45 to 65 years old
  • Both sexes
  • Hospitalized heart failure patients with ejection fraction \< 40%
  • Conscious and cooperative
  • Able to participate in training actively

Exclusion Criteria:

  • Acute major cardiovascular events (e.g., acute coronary syndrome, stroke, or pulmonary embolism)
  • Uncontrolled life-threatening arrhythmias
  • Severe valvular heart disease requiring urgent surgery
  • Pregnancy
  • End-stage renal disease requiring dialysis
  • Significant pulmonary diseases such as pulmonary arterial hypertension,
  • Implanted pacemaker
  • Clinically significant peripheral vascular disease
  • Severe anemia
  • Exercise-induced angina or ST-segment changes

Study details
    Decompensated Heart Failure

NCT07506499

Beni-Suef University

13 May 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.